Clinical trials: Adult Respiratory Distress Syndrome
Respiratory Distress Syndrome
Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants
To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
- Trial name
- NCT00807235
- Testing
- Aerosolized lucinactant
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Windtree Therapeutics
COVID-19, Coronavirus Disease 2019
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
- Trial name
- NCT04459325
- Testing
- Tigerase® and best available care, Best available care
- Where
- 6 sites in Russia
- Volunteers
- 100 people
- Sponsor
- AO GENERIUM
Parenteral Nutrition
Different Lipid Emulsions in Acute Lung Injury Patients
Aim is to investigate the influence of an early supply of parenteral nutrition including a fish oil containing lipid emulsion on the course of acute lung injury in the intensive care unit.
- Trial name
- NCT01814956
- Testing
- Lipoplus 20%, Lipofundin N 20%
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- B. Braun Melsungen AG
ARDS
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe…
- Trial name
- MACoVIA (NCT04367077)
- Testing
- MultiStem
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Healios K.K.
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
COVID-19, ARDS
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part is an open-label, single-arm, dose-escalating study to evaluate the safety and explore the dose limiting toxicity and maximum tolerated dose of…
- Conditions
- COVID-19, ARDS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04452097
- Testing
- Human umbilical cord mesenchymal stem cells + best supportive care
- Sponsor
- Baylx Inc.
Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS)
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied.
- Trial name
- SeeMe Tool (NCT06272942)
- Testing
- An ICU admission and a temporally related ARDS diagnosis
- Where
- United States
- Volunteers
- 640,058 people
- Sponsor
- Bayer
Acute Lung Injury
Study of Renin-angiotensin System in Mechanically Ventilated Subjects
The purpose of this study is to assess whether circulating Angiotensin (Ang) II and Ang (1-7) levels are associated with right ventricular (RV) dysfunction in mechanically ventilated subjects.
- Trial name
- NCT03212690
- Testing
- Local standard of care, Mechanical ventilation
- Where
- 2 sites in France
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare
Respiratory Distress Syndrome, Adult
Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
- Trial name
- ONE-BRIDGE (NCT03807804)
- Testing
- HLCM051
- Where
- 29 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Healios K.K.
Ventilators, Mechanical, Stroke
Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
The goal of this observational study is to compare pulmonary health parameter measurements from the VQm PHM™ to existing clinical measurements.
- Conditions
- Ventilators, Mechanical, Stroke, COPD, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06147674
- Testing
- VQm Pulmonary Health Monitor™
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 150 people
- Sponsor
- Rostrum Medical Innovations Inc.
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
ARDS (Acute Respiratory Distress Syndrome)
Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)
This is a Phase I/II, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of GKL-006RTU injection in participants with moderate to severe Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07706855
- Testing
- GKL-006RTU injection
- Volunteers
- 52 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
Acute Respiratory Distress Syndrome (ARDS), Pneumonia
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease), Postoperative Respiratory Distress
- Trial name
- NCT07432191
- Testing
- INBENTUS VERSATILE
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Iconic Solutions By Murcia SL
Respiratory Distress Syndrome in Premature Infant
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
- Trial name
- NCT03969992
- Testing
- AeroFact, nCPAP
- Where
- 41 sites in United States, Canada
- Volunteers
- 261 people
- Sponsor
- Aerogen Pharma Limited
COVID-19 Acute Respiratory Distress Syndrome
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog)…
- Trial name
- NCT05083117
- Testing
- XW001
- Where
- 2 sites in Argentina, Peru
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.